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HC administration, and reached the maximal value (19.2pg/ml)
at the end of 24hours considerably exceeding that in the control
group (3pg/ml). Therefore, after immunizationwithHC, leukocytes
producedTh1, Th2andTh17cytokines,whichplay thedifferent role
in the immune response regulation. The obtained data explain the
predominant production, in mice immunized with HC, of IgG1 and
IgG2a subisotypes to the capsular polysaccharide of S. pneumoniae
14, which are connected with IL-5 and IFN production respec-
tively. IL-17 produced by CD4+IL17+ stimulates the protection from
extracellular bacteria including S. pneumoniae that was proved by
challenging immunized mice with a lethal dose of S. pneumoniae
type 14. As a result, all immunizedmice survived as comparedwith
10% survival in the control group.
Conclusion: The ability of the hexasaccharide conjugate to
stimulate production of Th1, Th2 and Th17 cytokines with the
following production of IgG antibodies to the capsular polysaccha-
ride explains its protective activity in mice after challenge with
S.pneumoniae type 14.
http://dx.doi.org/10.1016/j.ijid.2014.03.1327
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Comparison of immunogenicity elicited by two
prime-boost strategies against tuberculosis
M. Lu ∗, L. Bao
West China Center of Medical sciences, Sichuan
University, Chengdu, China
Background: Tuberculosis remains a major health problem
worldwide, and the efﬁcacy of the only available vaccine Bacille
Calmette-Guérin (BCG) varies from 0% to 80%. It is extremelyur-
gentto ﬁnd new vaccine candidates and develop novel vaccine
approaches. The disease is caused by Mycobacterium tuberculo-
sis whose preferred habitat is the host macrophage, and cellular
immune responses are important in against intracellular bacte-
rial infection. An efﬁcacious tuberculosis (TB) vaccinewill probably
need to induce both CD4+and CD8+T-cell responses speciﬁc to a
protective Mycobacterium tuberculosis antigen(s). The gene Rv1769
has been lost from BCG-Pasteur1173 in vitro subculture, and some
studies have demonstrated that it is excellent T cell antigen. To
evaluate its immunogenicity, we used the prime-boost strategy to
immunize BALB/c mice and detected its cellular immune response.
Methods&Materials: In our research, we immunized 4-5week
old pathogen-free BALB/cmalemice byDNA/DNAandDNA/protein
prime-boost vaccination strategies. Mice were killed 4, 8, 12, 16
weeks after the last boost, and we detected antibody titers in the
serum, the proliferation rate of splenocytes, percentage of CD4+
and CD8+ T cells in the splenocytes and the IFN- and IL-4 levels
in special antigen-stimulated splenocyte cultures to measure its
immunogenicity. Measurement of these data are expressed as the
mean± standard errors(S.E.). Differences among the groups were
analyzed by one-way ANOVA and differences between two groups
wereanalyzedbyPostHocTest and thedifferenceswereconsidered
statistically signiﬁcant for P <0.05.
Results: Our data suggests that our novel DNA/DNA using
Rv1769 vaccine could elicit the most long-lasting and strongest
Th1 type cellular immune responses involving CD4+ and CD8+ T
cells. This response is characterized by a strong antibody response,
the proliferation rate of splenocytes, a high percentage of CD4+
and CD8+ T cells and high levels of IFN- in antigen-stimulated
splenocyte cultures.
Conclusion: Our results provide evidence that the gene Rv1769
is a potential antigen or subunit vaccine to TB for further study, and
in the future, we would consider build an in vivo challenge model
to extend our ﬁndings to an infection/disease protection system.
http://dx.doi.org/10.1016/j.ijid.2014.03.1328
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Background: We evaluated the feasibility and acceptability of
a new presentation of liquid DTP-HepB-Hib vaccine in a UnijectTM
device in Senegal and Vietnam.
Methods&Materials:We conducted306 interviews, nine focus
groupsessions, observationsof immunizationsessions (using injec-
tion into an orange), and a desk review of national programmatic
documents. Interviews were conducted with health workers, pro-
fessional representatives, andcaretakers.Weassessed the logistical
impact of UnijectTM with theWHO-developed immunization logis-
tics planning tool.
Results: Interviewees emphasizedefﬁcacy and safety as key fac-
tors for acceptability of a new device and most perceived that the
UnijectTM device represented an improvement over existing vac-
cine presentations. Compared to current presentations, UnijectTM
reducedvaccinewasteweight andvolume, including thenumberof
empty vials (from 51% in Vietnam to 68% in Senegal). By bundling
needles and syringes, UnijectTM reduced the potential for stock-
outs of one or the other. Time per vaccinated child decreased by
27%-61% depending on the setting.Each country used more than
one DTP-HepB-Hib vaccine presentation, and UnijectTM decreased
overall cold chain requirements formost butnot all of thesepresen-
tations. Informants reported thatUniject’sTM relatively lightweight
compared to traditional auto-disabled syringes should facilitate
both outreach and mobile strategies. Challenges also were identi-
ﬁed. As a novel injection device, some stakeholders may require
reassurance that UnijectTM represents contextually appropriate
technology. Vaccinator training will be required to address several
technical issues (e.g., activating the device and themotion required
for vaccine delivery) and perceptions (e.g., that the plastic reservoir
might freeze more easily and be difﬁcult to handle). A key concern
was that the UnijectTM device was used already in Senegal for con-
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traceptives, and thus UnijectTM for vaccines would need to have
distinctive distinguishing characteristics (shape, color, labeling) to
avoid negative impact on immunization programs.
Conclusion: UnijectTM has signiﬁcant advantages over tradi-
tional vaccine presentations with respect to perceptions of device
safety and efﬁcacy, reductions in waste, bundling of syringe and
needle, and time needle to vaccinate a child.While challengeswere
identiﬁed, most of these could be overcome through vaccinator
training, minor device modiﬁcations, and social mobilization.
http://dx.doi.org/10.1016/j.ijid.2014.03.1329
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Potency status of oral polio virus vaccine
among retrieved ﬁeld samples in Kenya
J.A. Hassan1,∗, G. Gachara2, F. Mbugua1, J.
Muchiri 1, S. Symekhah1, G. Nakitari1, P. Borus3,
T. Kamau4, J. Kombich5
1 Kenya Medical Research Institute, Nairobi, Kenya
2 Kenyatta university, Nairobi, Kenya
3 WHO, Nairobi, Kenya
4 DVI, Nairobi, Kenya
5 Kabian university, Kericho, Kenya
Background: In 1988 the World Health Organization (WHO)
proposed mass immunization campaigns with the trivalent oral
polio vaccine (TOPV) among children less than 5 years of age. The
VaccineVialMonitor (VVM) is a small patch of heat-sensitivemate-
rial placed on the vaccine vial to register cumulative heat exposure.
A direct relationship exists between the rate at which the VVM
changes colour and ambient temperature. This in turn affects the
potency of the oral polio vaccine. [1]
Objectives: To evaluate the status of the cold chain infrastruc-
ture in Kenya and to determine the total TOPV virus concentration
of retrieved ﬁeld samples.
Methods & Materials: A stratiﬁed multi-stage sampling strat-
egy was used leading to selection of 14 health centres this study. A
total of 23TOPVvial sampleswere collected, separated into individ-
ual serotypes generating 69 samples for the potency test. Potency
of oral polio vaccine was tested using Karber’s formula. This was
then compared to the Vaccine Vial Monitor stage of the vials
Results: Our study showed that the average potency of polio
vaccine serotype1, serotype 2 and serotype 3 were as follows;
Comparison between VVM1/VVM 2 and Serotype titres calcu-
lated
Polio 1
standard
(Mean titre)
Polio 1 Test
(Calculated
Mean Titre)
Polio 2
standard
(Mean titre)
Polio 2 test
(Calculated
mean Titre)
Polio 3
Standard
(Mean titre)
Polio 3 test
(Calculated
mean Titre)
VVM
106 106.05 105 104.98 105.5 105.73 1
106 106.03 105 105.08 105.5 105.35 2
*The mean titre was calculated using the Karber’s formula[Log
CCID50 = L-d(S-0.5)]]with an allowance of +0.5 log units
Conclusion: On average the vaccine vials used in the studywere
potent with satisfactory VVM and mean serotype titre. We found
that someOPVvials haddissatisfactoryVVMstage. Vaccinepotency
was seen to be directly proportional to VVM stage of vaccine vials.
Vaccine vials kept at temperatures below -18 ◦C had a better VVM
leading to a better potency status. Some OPV Samples which had
lower titre of serotype 2 were contributed to by the temperature
of the equipment they were stored at.
References: Samant Y, Lanjewar H, Block L, Parker D, Stein B,
Tomar G. Relationship between vaccine vial monitors and cold
chain infrastructure in a rural district of India. Rural and Remote
Health 7: 617. (Online) 2007. Available: http://www.rrh.org.au
http://dx.doi.org/10.1016/j.ijid.2014.03.1330
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Platlet transfusion in dengue fever: use or
misuse?
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Background: Dengue is a global health problem.Platlet transfu-
sions areused in the treatment of patientswithdengue fever.Indian
guidelines promote platlet transfusions in patients with platlet
counts of less than 10,000.The main aim of our study was to deter-
mine how platlets were being used in dengue fever at a tertiary
care centre in South India.
Methods & Materials: This retrospective study was conducted
in the hospitals attached to Kasturba Medical College, Mangalore.
During the study period of one year any patientwith fever and pos-
itive IgM dengue or NS1 antigen positive was considered to have
dengue fever. Criteria for appropriate platelet transfusion was pro-
phylactic platelet transfusion for patientswithplatelet count of less
than 10000 cells per cumm or therapeutic platelet transfusion for
patients with bleeding manifestations of WHO bleeding category
III and IV.
Results: A total number of 261 dengue cases were analysed.
197 (75.48%) patients were males. The mean age of study popula-
tion was 33.74 years. Platelet transfusion was administered to 62
patients. 19 transfusions were appropriate, out of which 13 were
prophylactic and 6 were therapeutic platelet transfusions. In 43
(69.35%) patients transfusions was inappropriate.
Conclusion: Majority of platlet transfusions in our study was
inappropriate. Appropriate use of platelet concentrates should
be ensured for patients in whom it is really indicated, as it
avoids unnecessary risk of transfusion reactions and blood borne
infection.
http://dx.doi.org/10.1016/j.ijid.2014.03.1331
